Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency

Background: Once-weekly TransCon hGH (lonapegsomatropin) is an investigational long-acting prodrug of somatropin in development for GHD. In the pivotal 52-week phase 3 heiGHt trial, lonapegsomatropin demonstrated superior annualized height velocity (AHV) compared to the same weekly dose of daily som...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Hofman, Paul, Saenger, Paul, Chertok, Elena, Aghajanova, Elena M, Song, Wenjie, Mao, Meng, Chessler, Steven D, Komirenko, Allison, Beckert, Michael, Shu, Aimee D, Thornton, Paul S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Pediatric Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1378
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados